Accendra Health Earnings Call Transcripts
Fiscal Year 2026
-
Q3 results missed expectations, with adjusted EBITDA of $47.8 million and revenue down 1% excluding specified impacts. A turnaround targets referral growth, patient retention, collections, and cost efficiency; FY 2026 adjusted EBITDA is now expected up to 30% below prior guidance midpoint.
-
Second quarter results missed expectations due to revenue growth and collection rate challenges, but operational improvements, cost reductions, and new commercial agreements are expected to drive stronger performance in late 2026 and 2027. Debt was reduced by $400 million, and free cash flow is projected to be break-even for 2026.
-
The meeting approved all four proposals, including director elections and incentive plan. The company highlighted its transition to a pure play home-based care provider, serving most of the U.S. with a streamlined workforce and strong brand presence.
-
First quarter 2026 results met expectations, with revenue down 6.8% year-over-year but up 1% excluding a major payer exit. Gross margins nearly doubled post-divestiture, and a comprehensive balance sheet optimization will reduce debt and extend maturities.
Fiscal Year 2025
-
Revenue grew over 3% in 2025 to nearly $2.8B, with strong performance in sleep, ostomy, and urology. 2026 guidance reflects a $300M revenue headwind from a major payer loss, but cost reductions and technology investments are expected to support margins and cash flow.
-
Announced sale of Products and Healthcare Services segment, shifting focus to higher-margin Patient Direct home-based care. Q3 revenue grew modestly, with strong performance in sleep therapy and ostomy, while guidance for 2025 was affirmed. Free cash flow and margins are expected to improve post-divestiture.
-
Q2 2025 saw 3.3% revenue growth and margin expansion, with Patient Direct driving results amid the P&HS divestiture. Guidance for 2025 is $2.76–$2.82B revenue and $376–$382M adjusted EBITDA, with all divestiture proceeds to reduce debt.
-
Q1 2025 saw mid-single digit revenue growth and 31% operating income growth in patient direct, with strong performance across therapy categories. Tariff exposure of $100–$150 million is being addressed through targeted price increases, and guidance for 2025 is reaffirmed.
Fiscal Year 2024
-
Mid-single-digit revenue growth and 13% adjusted EPS growth were achieved in 2024, with strong patient-direct performance and significant debt reduction. 2025 guidance anticipates continued growth, a $100 million share repurchase, and the Rotech acquisition, while the P&HS segment sale process advances.
-
Q3 2024 saw 5% revenue growth, strong Patient-Direct demand, and significant debt reduction. Guidance for 2024 was refined due to supply chain and procedural volume headwinds, but sequential growth and improved cash flows are expected into Q4 and 2025.
-
Q2 revenue grew 4% year-over-year to $2.7B, with both segments contributing and profitability improving. The Rotech acquisition will expand Patient Direct, and strong cash flow is expected in H2, supporting reaffirmed 2024 guidance.
-
The acquisition of Rotech for $1.36 billion in cash will expand the Patient Direct segment, diversify the product and payer mix, and accelerate growth toward a $5 billion revenue target by 2028. Management expects $50 million in synergies by year three, with the deal accretive to margins and EPS from year two.